Concerto HealthAI and Pfizer Oncology are expanding a collaboration using real-world data (RWD) to advance study design to include a range of cancers, including prostate cancer.
The expansion builds on a partnership announced last April to advance precision oncology using Concerto’s eurekaHealth platform, artificial intelligence (AI) models and real-world clinical electronic medical record (EMR) and healthcare claims.
The collaboration will include claims data linked to clinical EMR data and linked next-generation sequencing information for research and potential regulatory purposes, the companies said.
Pfizer will use Concerto’s eurekaHealth 3.0, a real-world evidence (RWE) enterprise solution that integrates real-world data with artificial intelligence-powered tools and models.
The companies’ goal is to advance the pace of actionable patient insights into Pfizer‘s therapies for solid tumors and hematologic malignancies in prostate, breast, lung and renal cells.
“We are looking forward to expanding our collaboration with Concerto HealthAI and exploring the application of analytics to RWD for generating RWE in genitourinary cancers, a key area of our oncology strategy,” Chris Boshoff, MD, PhD, chief development officer for oncology in Pfizer’s global product development division, said in a press release.
A joint Concerto-Pfizer steering committee will oversee the collaboration, which uses RWD from, among other data sources, the American Society of Clinical Oncology’s CancerLinq program, a health information technology platform aimed at enhancing the understanding and treatment of cancer. The companies expect to publish the first research resulting from the collaboration by mid-2020.
“This expanded collaboration aims to find and help patients with some of the most devastating cancers,” said Jeff Elton, PhD, CEO of Concerto HealthAI. “We believe that use of our high-precision, research-grade RWD, AI solutions, and scientific expertise can advance innovative study designs, like external control arms, providing confidence in the interpretation of study results and accelerated execution.”
After skin cancer, prostate cancer is the most common cancer in men in the U.S. About 191,930 new cases are expected to be diagnosed this year. One in nine men will be diagnosed with the disease during his lifetime.